Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MB-106 in R/R B-Cell NHL or CLL
NCT05360238Phase 2Terminated
- Sponsor
- Mustang Bio
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of MB-106 in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), sponsored by Mustang Bio. Started May 2022; status: terminated.
02
Drugs
MB-106
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05360238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360238.